| Literature DB >> 22179068 |
Christian Laggner1, David Kokel, Vincent Setola, Alexandra Tolia, Henry Lin, John J Irwin, Michael J Keiser, Chung Yan J Cheung, Daniel L Minor, Bryan L Roth, Randall T Peterson, Brian K Shoichet.
Abstract
Target identification is a core challenge in chemical genetics. Here we use chemical similarity to computationally predict the targets of 586 compounds that were active in a zebrafish behavioral assay. Among 20 predictions tested, 11 compounds had activities ranging from 1 nM to 10,000 nM on the predicted targets. The roles of two of these targets were tested in the original zebrafish phenotype. Prediction of targets from chemotype is rapid and may be generally applicable.Entities:
Mesh:
Year: 2011 PMID: 22179068 PMCID: PMC3262069 DOI: 10.1038/nchembio.732
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040
Figure 1The number of compounds for which at least one target is predicted as a function of expectation value vs. random (E-value)
Higher E-values are less stringent. Only E-values below (better than) 10−5 were considered in this analysis.
Target predictions, E-values (ECFP4), maximum Tanimoto coefficient and binding affinities for compounds active in the Zebrafish photomotor response screen.
| Cpd. | PMR Plot | Predicted | E-value | Max. TC | Ki (nM) |
|---|---|---|---|---|---|
| β1 AR | 2.99×10−18 | 0.47 | 337 | ||
| β2 AR | 4.69×10−15 | 0.43 | 728 | ||
| β3 AR | 4.55×10−19 | 0.47 | 589 | ||
| β1 AR | - | - | 965 | ||
| β2 AR | 2.98×10−05 | 0.61 | 550 | ||
| β3 AR | 2.98×10−05 | 0.61 | 3128 | ||
| dopamine D2 | 3.54×10−33 | 0.63 | 120 | ||
| dopamine D3 | 8.16×10−41 | 0.63 | > 10,000 | ||
| dopamine D4 | 1.00×10−24 | 0.49 | 5.0 | ||
| α1A AR | 2.07×10−48 | 0.49 | 113.6 | ||
| α1B AR | 1.19×10−48 | 0.49 | 29.7 | ||
| α1D AR | 3.89×10−48 | 0.49 | 25.4 | ||
| α2A AR | 2.01×10−27 | 0.43 | 164 | ||
| α2B AR | 2.83×10−26 | 0.43 | 96.4 | ||
| α2C AR | 1.84×10−26 | 0.43 | 80.8 | ||
| 5-HT1A | 3.83×10−67 | 0.53 | 65.0 | ||
| 5-HT1B | 1.62×10−16 | 0.49 | 9422 | ||
| 5-HT1D | 7.55×10−17 | 0.49 | 153 | ||
| dopamine D2 | 2.78×10−42 | 0.55 | 4869 | ||
| dopamine D3 | 1.46×10−46 | 0.58 | 946 | ||
| dopamine D4 | 2.25×10−49 | 0.58 | 1181 | ||
| 5-HT1A | 1.24×10−31 | 0.53 | 2439 | ||
| 5-HT1B | 1.61×10−12 | 0.53 | > 10,000 | ||
| 5-HT1D | 2.32×10−16 | 0.53 | 4512 | ||
| dopamine D2 | 2.15×10−38 | 0.66 | 207 | ||
| dopamine D3 | 9.25×10−44 | 0.65 | 164 | ||
| dopamine D4 | 8.28×10−25 | 0.47 | 530 | ||
| Kv1.1 | 4.05×10−71 | 0.72 | n.d. | ||
| Kv1.2 | 9.40×10−85 | 0.72 | 1930 | ||
| Kv1.3 | 1.28×10−14 | 0.72 | n.d. | ||
| Kv1.1 | 9.69×10−56 | 0.56 | n.d. | ||
| Kv1.2 | 1.18×10−66 | 0.56 | 2810 | ||
| Kv1.3 | 1.74×10−10 | 0.56 | n.d. | ||
| oxytocin | 1.60×10−26 | 0.52 | > 10,000 | ||
| vasopressin | 8.32×10−10 | 0.52 | 690 | ||
| 1A | |||||
| SERT | 2.06×10−19 | 0.52 | 6200 | ||
| ABL2 | 1.62×10−54 | 0.42 | 7460 | ||
| SRC | 3.38×10−34 | 0.42 | 3820 | ||
| LCK | 2.51×10−30 | 0.45 | 1890 | ||
| p38α | 2.68×10−10 | 0.42 | 47% Inh. | ||
The aggregate motor activity of 10 zebrafish embryos during the PMR assay. The y-axis and x-axis represent the motion index and time, respectively. Red vertical bars at 10s and 23s represent the timing and duration of the stimulus.
Calculated with Daylight fingerprints (note that TC values are not comparable across different fingerprints; Daylight fingerprints usually give higher TC values than ECFP4 for the same compound pairs).
IC50 (nM).
EC50 (nM).
Assuming competitive inhibition, and based on the Cheng-Prusoff equation, Ki values would be about half the IC50 values for the kinase inhibitors.
Figure 2Testing target relevance by phenocopy and functional competition. Compounds 6 and 7 phenocopy the known Kv inhibitor psora-4 (12)
The PMR phenotypes of animals treated with (a) DMSO, (b) compound 12, (c) compound 6. The same phenotype was obtained for compound 7 (see Table 1). (d) Bar plot showing the mean number of motor activity spikes in animals treated with DMSO, compound 12, compound 7, and compound 6. Activities during background, excitation and refractory phases of the PMR are shown. Compound 1 suppresses β-AR agonist-induced motor excitation. The PMR phenotypes of animals treated with: (e) compound 13 (isoproterenol), (f) compound 13 and the known β-AR antagonist compound 14 (bopindolol) together (g) compounds 13 and 1. (h) Bar plot showing the mean number of motor activity spikes in animals treated with DMSO, compound 13, compounds 13 and 14, and compounds 13 and 1. Activities during background, excitation and refractory phases of the PMR are shown. Bars in panels d and h represent mean values ± s.d.